U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Novo Nordisk , whose global profile has risen along with demand for its Wegovy weight-loss drug, is bolstering operations in ...

Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Novo Nordisk’s stock declined 12% in the past month. Wegovy's sales growth stays under pressure. Read why I'm neutral on NVO ...

Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

The $200B GLP-1 market is set to expand with 16 new obesity drugs launching by 2029, challenging Novo Nordisk and Eli Lilly's ...

One of the downsides of treatments such as Ozempic or Mounjaro is that even though patients wind up losing weight, they also tend to shed muscle mass. Losing too much muscle mass can be a health risk ...

WeightWatchers said on Tuesday it would offer a compounded version of Novo Nordisk's popular obesity drug Wegovy as part of ...

Not only did I not know that longtime local brewery Novo Brazil had opened a new spot in the Mission Valley Mall, but I also ...